SCHEMBL3525540

SCHEMBL3525540

COC(=O)CCc1cc2c(Cl)c(Cl)ccc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARG P37231 14/20 0.52
PPARA Q07869 12/20 0.52
PPARD Q03181 8/20 0.52
MTNR1B P49286 1/20 0.46
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
PTGDR Q13258 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
HTR6 P50406 1/20 0.39
KDM4E B2RXH2 1/20 0.38
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527594 0.88 PPARG (0.66) PPARGPPARAPPARDMTNR1BPTGDR
SCHEMBL3525871 0.83 PPARG (0.59) PPARGPPARAPPARDMTNR1BCYP11B1
SCHEMBL3528397 0.82 PPARG (0.78) PPARGPPARAPPARD
SCHEMBL3523098 0.80 PPARG (0.58) PPARGPPARAPPARDMTNR1BCYP11B1
SCHEMBL3524904 0.79 PPARG (0.55) PPARGPPARAPPARDMTNR1BCYP11B1
SCHEMBL3526398 0.78 PPARG (0.72) PPARGPPARAPPARDMTNR1B
SCHEMBL3524268 0.77 PPARG (0.58) PPARGPPARAPPARDMTNR1BPTGDR
SCHEMBL3521759 0.77 PPARG (0.58) PPARGPPARAPPARDCYP11B1CYP11B2
SCHEMBL3523487 0.77 PPARG (0.54) PPARGPPARAPPARDCYP11B1CYP11B2
SCHEMBL3525614 0.77 PPARG (0.57) PPARGPPARAPPARDMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP PPARG 1018/4885PPARA 847/4885PPARD 677/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG PPARG 3/4885PPARA 2/4885PPARD 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.